touchPODCAST

touchPODCAST

By touchpodcastScience
Download on the App Store

touchPODCAST episodes

  • MDT and patient perspectives on the diagnostic tools for non-CF bronchiectasis

    touchMDT for touchRESPIRATORY

    Listen to key experts from a multidisciplinary team, and a patient, review the diagnostic tools for non-CF bronchiectasis.

    The multidisciplinary team 

    • Primary care physician: Professor Barbara Yawn, USA
  • Pulmonologist: Professor James Chalmers, Scotland
  • Radiologist: Professor Mary Salvatore, USA
  • Patient: Marta Almagro, Spain

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Insmed. This medical education is jointly provided by USF Health and touchIME.


    For further information visit: touchRESPIRATORY

    14 min
  • MDT and patient perspectives on the clinical presentation of non-CF bronchiectasis touchRESPIRATORY

    Listen to key experts from a multidisciplinary team, and a patient, explore the key signs and symptoms of non-CF bronchiectasis and how these inform the clinical diagnosis.


    The multidisciplinary team 

    • Pulmonologist: Professor James Chalmers, Scotland
  • Primary care physician: Professor Barbara Yawn, USA
  • Patient: Marta Almagro, Spain

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Insmed. This medical education is jointly provided by USF Health and touchIME.

    For further information visit: touchRESPIRATORY

    15 min
  • MDT perspectives on the pathophysiology and comorbidities of non-CF bronchiectasis touchRESPIRATORY

    Listen to key experts from a multidisciplinary team discuss the pathophysiology and comorbidities of non-CF bronchiectasis.

    The multidisciplinary team

    • Primary care physician: Professor Barbara Yawn, USA
  • Pulmonologist: Professor James Chalmers, Scotland

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Insmed. This medical education is jointly provided by USF Health and touchIME.


    For further information visit: touchRESPIRATORY

    12 min
  • Experts discuss latest guidelines and how novel treatments can reduce ASCVD risk in patients with dyslipidemias

    touchIN CONVERSATION for touchCARDIO

    Listen to Prof. Kausik Ray in conversation with Dr Mahir Karakas. They respond to questions submitted by the HCP audience and provide their expert insights on how the latest guidelines and treatments can be applied to reduce ASCVD risk in patients with dyslipidemias. 

     

    This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical educational grant from Novartis. This activity is provided by  touchIME.

     

    For further information visit our website:

    https://touchendocrinologyime.org/in-conversation-guidelines-novel-therapies-emerging-options-for-managing-dyslipidemias-ASCVD-risk

    31 min
  • Experts in endocrinology and in primary care discuss addressing cardiorenal outcomes in CKD and T2D

    touch INCONVERSATION for touchENDOCRINOLOGY

     

    Listen to Prof. Peter Rossing in conversation with Dr Eden Miller. They respond to questions submitted by the HCP audience and provide their expert insights on monitoring CKD progression, reducing the risk of cardiorenal outcomes, and applying the latest guidelines on CKD and T2D to daily practice.

    This touchPODCAST is for HCPs only.

    his activity is funded by an unrestricted independent medical educational grant from from Bayer. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website:

    https://touchendocrinologyime.org/in-conversation-addressing-cardiorenal-outcomes-in-CKD-and-T2D

    39 min
  • Experts in endocrinology and in primary care discuss addressing cardiorenal outcomes in CKD and T2D

    touch IN CONVERSATION for touchCARDIOLOGY

     

    Listen to Prof. Peter Rossing in conversation with Dr Eden Miller. They respond to questions submitted by the HCP audience and provide their expert insights on monitoring CKD progression, reducing the risk of cardiorenal outcomes, and applying the latest guidelines on CKD and T2D to daily practice.


    This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical educational grant from Bayer. This activity is jointly provided by USF Health and touchIME.


    For further information visit our website:
    https://touchcardioime.org/in-conversation-addressing-cardiorenal-outcomes-in-CKD-and-T2D

    39 min
  • Getting personal: Individualizing therapy for cold agglutinin disease

    touchEXPERT OPINIONS for touchONCOLOGY

    Listen to two leading experts give their insights on the recommended workup for a timely and accurate diagnosis, as well as the evolving treatment landscape, and importance of individualizing therapy for patients with cold agglutinin disease. 

     

    The experts

    • Dr Catherine M Broome, MedStar Georgetown University Hospital Washington DC, USA
  • Dr Ilene Ceil Weitz, Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine Los Angeles, USA

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Alexion AstraZeneca Rare Disease and is jointly provided by USF Health and touchIME.

     

    For further information visit our website: https://touchoncologyime.org/getting-personal-individualizing-therapy-for-cold-agglutinin-disease/

    27 min
  • Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?

    touchPANEL DISCUSSION for touchIMMUNOLOGY

    Listen to a panel of leading experts discuss the pathophysiology of cold agglutinin disease (CAD), the steps needed for an accurate diagnosis, and how emerging treatment options are changing the management of patients with primary CAD. 

    The experts

    • Prof. Morie Gertz, Mayo Clinic, Rochester, Minnesota, USA
  • Prof. Bernd Jilma, Medical University of Vienna, Austria
  • Dr Shirley D'Sa, University College London Hospitals, UK

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME. 

    For further information visit: touchIMMUNOLOGY

    33 min
  • Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?

    touchPANEL DISCUSSION for touchONCOLOGY

    Listen to a panel of leading experts discuss the pathophysiology of cold agglutinin disease (CAD), the steps needed for an accurate diagnosis, and how emerging treatment options are changing the management of patients with primary CAD. 

    The experts

    • Prof. Morie Gertz, Mayo Clinic, Rochester, Minnesota, USA, 
  • Prof. Bernd Jilma, Medical University of Vienna, Austria, 
  • Dr Shirley D'Sa, University College London Hospitals, UK

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME. 

    For further information visit: https://touchoncologyime.org/understanding-the-immunopathogenesis-of-cad-what-are-the-implications-of-new-and-emerging-therapies

    33 min
  • Advances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022

    touchCONGRESS for touchONCOLOGY

    Listen to urological cancer expert Prof. Axel Merseburger (Germany) review key data presented at ESMO 2022 exploring recent advances in immunotherapies and targeted treatments for patients with bladder cancer.  He then offers his views on the potential impact of these data on clinical practice, alongside expert insights from Dr Bradley McGregor (USA) and Prof. Andrea Necchi (Italy). 

     

    OVERVIEW

    Data Review with Prof. Merseburger (00:00)

    Expert interviews with Prof. Merseburger, Dr McGregor and Prof. Necchi answering the questions below

    INTERVIEW QUESTIONS

    1. Based on data recently presented at ESMO 2022, how do you think new and emerging immunotherapy agents and targeted treatments for patients with bladder cancer will impact the treatment landscape? (31:45)
  • How can key learnings from ESMO 2022 be integrated into clinical practice when choosing between available regimens? (37:42)
  • How is our understanding of the role of PD-L1 as a biomarker in bladder cancer evolving in light of recent data, and what are the possible implications for clinical practice? (44:35)
  • What unmet needs remain surrounding biomarkers beyond PD-L1 in bladder cancer, and what are the prospects for biomarker-driven individualized treatment decisions in future? (51:14)

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical educational grant from Seagen Inc. and Astellas Pharma Inc. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website:

    https://touchoncologyime.org/bladder-cancer-esmo2022-touchcongress/https://touchoncologyime.org/bladder-cancer-esmo2022-touchcongress/

     

    59 min

About touchPODCAST

From the publisher's feed

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.